Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: German multicenter analysis of talquetamab in 138 patients with RRM finds ORR 65%, median PFS 6.4 months; prior BTCE exposure, ISS stage III, and extraosseous and penta-drug refractory disease associated with unfavorable outcomes.”
Authors: Jan Frenking, Christine Riedhammer, Raphael Teipel, Florian Bassermann, Britta Besemer, Ralph Wäsch, Romans Zukovs, Mathias Hänel, Leo Rasche, Marc Raab et al.
More posts featuring Robert Orlowski.
